The pharmaceutical landscape is currently approaching a seismic shift known as the “patent cliff.” For years, a handful of blockbuster specialty medications have dominated healthcare budgets, protected by a fortress of intellectual property. As these patents expire, the market is poised for an influx of competition that promises to redefine how plan sponsors manage their…
The landscape of pharmacy benefits is currently being reshaped by a new generation of medicine. For years, specialty spend has been dominated by biologics—complex, high-cost medications derived from living organisms. While these drugs have revolutionized the treatment of chronic conditions, they have also become the primary driver of unsustainable health plan costs. The solution lies…
In the complex ecosystem of pharmacy benefits, the “rebate wall” is one of the most significant obstacles to achieving true expense optimization. While the term may sound like a financial safeguard, it is actually a strategic hurdle used by drug manufacturers and Pharmacy Benefit Managers (PBMs) to protect high-cost, brand-name medications from lower-priced competition. For…
For decades, the pharmacy benefit industry has operated behind a curtain of complexity that serves the intermediary far more than the employer. We are currently navigating a marketplace where traditional Pharmacy Benefit Managers (PBMs) utilize intricate, proprietary ecosystems to generate significant revenue through methods that never appear on a line item. For plan sponsors, these…
For years, the pharmacy benefit industry has operated under a veil of complexity that makes it difficult for employers and brokers to determine if they are getting a fair deal. At the heart of this confusion are two competing financial models: Spread Pricing and Cost-Plus Pricing. While one relies on hidden margins and misaligned incentives,…
While it is easy to dismiss these terms as industry jargon, the specific benchmark used in a contract determines how much “invisible” profit a PBM can rake in. When a broker moves a client from an AWP-based contract to a more transparent model, they are essentially pulling back the curtain on traditional PBM’s profit centers….
The Illusion of Order in a Broken System The current state of the pharmacy benefit landscape is often described as a sophisticated, well-oiled machine. However, for those who look closely at the gears, it is clear the system is fundamentally broken. Traditional Pharmacy Benefit Managers (PBMs) have spent decades constructing a labyrinth of complex contracts…
When healthcare costs rise, CFOs don’t just want explanations. They want confidence. They are responsible for defending benefit decisions to leadership, managing financial risk, and ensuring resources are allocated responsibly. That means the questions they ask are rarely about tactics. They are about impact, accountability, and alignment. Brokers who can anticipate these questions and answer them clearly earn trust that extends far beyond…
For many employers, pharmacy conversations happen too late. Costs spike, renewal arrives, and decisions are made under pressure. By that point, options feel limited and trust is tested. A mid-year Rx review changes that dynamic. When used intentionally, it becomes one of the most effective ways brokers can strengthen client relationships and reinforce their role as strategic advisors. …
PBM contracts are often treated as definitive documents. Once signed, employers assume the terms clearly define how prescription benefits will be managed, how costs will flow, and how accountability will be enforced. In reality, PBM contracts often explain how things are priced without fully explaining how decisions are made. That gap matters. Especially as pharmacy spend continues to rise…